Ascendis says TransCon CNP achondroplasia trial shows continued leg-alignment gains at Week 104

Ascendis Pharma reported two-year data from its ApproaCH trial for TransCon CNP in achondroplasia patients. Presented at ICCBH 2026, results showed continued improvement in lower-limb alignment through Week 104, with stronger benefits in patients with preexisting leg bowing. The safety profile remained consistent over two years, featuring mostly mild-to-moderate side effects and no treatment discontinuations.

Ascendis Pharma disclosed 2-year data from its completed pivotal ApproaCH trial; results were presented at ICCBH 2026. * Once-weekly TransCon CNP showed continued improvement in lower-limb alignment in children with achondroplasia through Week 104. * Benefits appeared stronger in patients who entered the study with preexisting leg bowing, a complication that can drive pain and surgery. * Safety profile remained broadly consistent over two years, with mostly mild-to-moderate side effects and no treatment discontinuations reported. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300830PRIMZONEFULLFEED9754718) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Ascendis Pharma disclosed 2-year data from its completed pivotal ApproaCH trial; results were presented at ICCBH 2026. * Once-weekly TransCon CNP showed continued improvement in lower-limb alignment in children with achondroplasia through Week 104. * Benefits appeared stronger in patients who entered the study with preexisting leg bowing, a complication that can drive pain and surgery. * Safety profile remained broadly consistent over two years, with mostly mild-to-moderate side effects and no treatment discontinuations reported. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300830PRIMZONEFULLFEED9754718) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)